Tutorial: Data Mining for Drug Discovery and Development

Cao Xiao, Jimeng Sun

KDD' 19
























AI Assisted Medicine

Success in AI based diagnosis

Company	FDA Approval	Indication
Apple	September 2018	Atrial fibrillation detection
Aidoc	August 2018	CT brain bleed diagnosis
iCAD	August 2018	Breast density via mammography
Zebra Medical	July 2018	Coronary calcium scoring
Bay Labs	June 2018	Echocardiogram EF determination
Neural Analytics	May 2018	Device for paramedic stroke diagnosis
IDx	April 2018	Diabetic retinopathy diagnosis
Icometrix	April 2018	MRI brain interpretation
Imagen	March 2018	X-ray wrist fracture diagnosis
Viz.ai	February 2018	CT stroke diagnosis
Arterys	February 2018	Liver and lung cancer (MRI, CT) diagnosis
MaxQ-AI	January 2018	CT brain bleed diagnosis
Alivecor	November 2017	Atrial fibrillation detection via Apple Watch
Arterys	January 2017	MRI heart interpretation


Al based drug discovery and development








AI Accelerates Drug Discovery and Development






https://www.nytimes.com/2012/11/24/science/scientists-see-advances-in-deep-learning-a-part-of-artificial-intelligence.html

De novo structure prediction with deep-learning based scoring R.Evans, et al. In Thirteenth Critical Assessment of Techniques for Protein Structure Prediction (Abstracts) 1-4 December 2018.

T0955 / 5W9F

Eroom's Law in Pharmaceutical R&D




a Overall trend in R&D efficiency (inflation-adjusted)

Scannel et al., Diagnosing the decline in pharmaceutical R&D efficiency, Nature Reviews Drug Discovery, 2012

Causes of the Decline

- 1) Hard to improve over
 - existing drugs
- 2) cautious regulator
 - "throw money at it"
 - basic science-brute force

Traditional Drug Discovery & Development Process




		I		-	
	Drug discovery	Pre-clinical	Phase 1	Phase 2	Phase 3
Time spent	4-5 years	1-2 years	1-2 years	1-2 years	2-3 years
\$ spent	\$550M	\$125M	\$225M	\$250M	\$250M
Output	5,000 - 10,000 compounds	10-20 candidates	5-10 candidates	2-5 candidates	1-2 candidates




Approved for clinical use






AI/ML to the Rescue: Why and How?



Big pharmas show significant interests in Al



Novartis: A2A pharmaceuticals, Biovista, Watson **Merck**: Synthace, Cyclica, Atomwise, Numerate, Iktos **Roche**: Flatiron Health, Genialis, Exscentia, Owkin, Synapse, GNS **Sanofi:** Researchably, Benevolent AI, Exscentia, Berg Health **GSK**: Exscentia, Cloud Pharmaceruticals, Insilico Medicine

Biopharmatrend Report, Biopharmatrend Charts, GMInsights, Marketwatch,

Many AI start-ups in drug discovery

Competitor	Raised capital	Year funded	Employees	Approac
BenevolentAl	\$202M (\$2B val)	2013	51-100	Drug discovery, clinical trial simula mechanism of disease with know
flatiron Roche	(\$1.9B val)	2012	251-500	External control arms (EHR), anal and genomic data
heal×	\$61.9M	2014	11-50	Drug repositioning with knowledg
GNS HEALTHCARE	\$54.3M	2000	101-250	Drug discovery, clinical trial simula mechanism of disease with know
👌 Atomwise	\$51.3M	2012	11-50	Drug discovery with chemoinforn
Exscientia DRIVEN BY KNOWLEDGE	\$43.7M	2012	11-50	Drug discovery from AI to experim chemoinformatics and phenotyp
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	\$18.1M	2016	11-50	Drug discovery, clinical developme knowledge graphs
twoKAR	\$14.3M	2014	11-50	Drug discovery, clinical trial simula and biomolecular data

ch

Ilation, biomarker ID, **wledge graphs**

alysis through linked EMR

lge graphs

Ilation, biomarker ID, **vledge graphs**

matics and CNNs

mental, using pic screening

ment optimization through

lation with linked EHR

Why drug discovery & development is interesting to data mining community



- Compound databases
- Protein databases
- Disease knowledge •
- Biochemical literature
- Clinical trial data



- Feature vectors
- Graphs
- Sequences
- Text





Challenges

 High-dimensional • Small sample size Lack of labels Complex interaction














Entities of Drug Discovery Modeling



Entities of Drug Discovery Modeling



Data Encoding: Molecule Compounds (1D)




Aspirin molecule.

1-D descriptors

Weight, solubility, charge, number of rotatable bonds, atom types, topological polar surface area

Formally, acetylsalicylic acid

Data Encoding: Molecule Compounds (2D)




2-D Descriptor

taking into account the graph of covalent and aromatic bonds, but not spatial coordinates.

Aspirin molecule.


Entities of Drug Discovery Modeling



Protein Targets

Biology 3-D structure

A Sequence of 23 Amino Acids





GO term Protein Function


Gene Sequence

Double Helix DNA structure


A-T, C-G allele representation







Entities of Drug Discovery Modeling




Disease

ICD code	ICD description
Acute rheumatic fever codes	
100.	Rheumatic fever without mention of heart involvem
101.0	Acute rheumatic pericarditis
101.1	Acute rheumatic endocarditis
101.2	Acute rheumatic myocarditis
101.8	Other acute rheumatic heart disease
102.0	Rheumatic chorea with heart involvement
102.9	Rheumatic chorea without heart involvement



Biomedical Entities in the Knowledge Graph














Modeling Tasks Covered in This Talk



2. Drug repositioning

3. Adverse drug Reaction/interaction


Input and Output of Modeling Tasks

1. Molecule Property Prediction

f (70 Q

0. Molecular Representation Learning

2. Drug repositioning



Molecule + protein




Drug molecule embedding

3. Adverse drug Reaction/interaction

hog ho f (%


Molecule + molecule interactions

4. De Novo Design




Affinity Score





0.Molecular Representation Learning

Molecular Graph




Molecular Graph

A molecule compound is a distinct group of atoms held together by chemical bonds.


Molecules with similar descriptors have similar properties.

Molecular representation learning is a fundamental task for in silico modeling.

Molecular Graph Representation: Overview




Drug molecular Low dimensional descriptors embeddings



Intuition: Map raw drug molecular data to low dimensional embeddings such that similar molecules are embedded close together

Traditional Molecular Representation



- 1. Need to represent a **Structure** by a characteristic vector of numbers (descriptors),
- 2. Should include propertyrelevant aspects
- 3. Atom arrangement in **Space**

Traditional Molecular Representation (1D)

1-D Descriptor

experimental and calculated molecular properties that do not account for a molecule's bond structure: weight, solubility, charge, number of rotatable bonds, atom types, topological polar surface area

- 1. Need to represent a **Structure** by a characteristic vector of numbers (descriptors),
- 2. Should include **property**relevant aspects
- 3. Atom arrangement in **Space**


Traditional Molecular Representation (2D)

2-D Descriptor

taking into account the graph of covalent and aromatic bonds, but not spatial coordinates.

- 1. Need to represent a **Structure** by a characteristic vector of numbers (descriptors),
- 2. Should include propertyrelevant aspects
- 3. Atom arrangement in **Space**

Example of 2-D Representation (Circular Fingerprints)






Example of 2-D Representation (Circular Fingerprints)

Extended Circular Fingerprint (ECFPx)

1. Search the partial structures around each atom recurrently Identifiers: Diameter 0: -1266712900 → ^x ^x ^x _x ₀ ^{x *} -1216914295 78421366 -887929888 -276894788 Diameter 2: -744082560 -798098402 -690148606 1191819827 1687725933 1844215264 Diameter 4: -252457408 132019747 -2036474688 -1979958858 -1104704513 2. Assign an integer identifier

to each partial structure



Knowledge Based Molecular Representation Learning (3D)


3-D Descriptor

Further considers spatial coordinates.

- 1. Need to represent a structure by a characteristic vector of numbers (descriptors), e.g., # N Atoms; # Aromatic Rings.
- 2. Should include property-relevant aspects, e.g., neighborhoodinduced properties, and relative arrangement of atoms.
- 3. Atom arrangement in space,

structure by or of s), e.g., # N Rings. erty-relevant oorhoodand relative ns. n space,


Example of 3-D Representation (E3FP)



Extended Three-Dimensional Fingerprint (E3FP)

Simplified Molecular-Input Line-Entry System (SMILES)

Construction: Traverse the molecular graph in a depth-first manner following the atom with the smallest label at each branch point.




() are used to branches

COc(c1)cccc1C#N

SMILES

Matrix Representation for Molecules (Bond Adjacency)


A molecular structure with n atoms may be represented by an $n \times n$ matrix (H atoms are often omitted).






Matrix Representation for Molecules (Topological Distance)

Distance matrix : encodes the distances between atoms.






Molecular Representation Learning using Deep Neural Networks



y molecular property e.g., solubility, toxicity


Data Representation: deep neural networks

- Let's start with a simple Multi-layer Perceptron (MLP)
 - Binary classification: toxicity 0



Data Representation (deep neural networks)


- Learning the model parameters
 - Backpropagation + Gradient descent




learning molecular representation without labeled or with limited number of samples

Sentence <-> molecules

words <-> substructure



Jaeger et al., Mol2vec: Unsupervised Machine Learning Approach with Chemical Intuition. J Chem Inf Model 2018



Method: Generate word2vec embedding on ECFP integer identifiers (words). As each identifier corresponds to a substructure, one molecule structure corresponds to a SMILE string ("sentence")

Jaeger et al., Mol2vec: Unsupervised Machine Learning Approach with Chemical Intuition. J Chem Inf Model 2018

ESOL solubility data set25 : a regression task to predict aqueous solubility of 1144 compounds

Ames mutagenicity data set: a classification task to determine if is mutagenic of 6471 compounds

Tox21: classification task about 12 targets which were associated with human toxicity of 8192 compounds

Table 1. Performance of Mol2vec and Other Models on Regression Predictions of the ESOL Data Set

ML features	ML method	$R_{ m cv}^2$	MSE	MAE
descriptors	MLR	0.81 ± 0.01	0.82	0.69
molecular graph	CNN	0.82	-	-
molecular graph	CNN	-	-	0.52 ± 0.07
molecular graph	CNN	0.93	0.31 ± 0.03	0.40 ± 0.00
molecular graph	RNN	0.92 ± 0.01	0.35	0.43
Morgan FPs	GBM	0.66 ± 0.00	1.43 ± 0.00	0.88 ± 0.00
Mol2vec	GBM	0.86 ± 0.00	0.62 ± 0.00	0.60 ± 0.00

Table 2. Performance of Mol2vec and Other Methods on Classification Prediction of the Ames Data Set

ML features	ML method	AUC	sensitivity	specificity
descriptors	SVM	0.86 ± 0.01	-	-
descriptors and Morgan FPs	NBC	0.84 ± 0.01	0.74 ± 0.02	0.81 ± 0.01
Morgan FPs	RF	0.88 ± 0.00	0.82 ± 0.00	0.80 ± 0.01
Mol2vec	RF	0.87 ± 0.00	0.80 ± 0.01	0.80 ± 0.01

Table 3. Performance of Mol2vec and Other Methods on Classification Predictions of the Tox21 Data Set

ML features	ML method	AUC	sensitivity	specificity
molecular graph	CNN	0.71 ± 0.13	_	-
molecular descriptors and FPs	SVM	0.71 ± 0.13	-	-
molecular descriptors and FPs	DNN	0.72 ± 0.13	-	-
Morgan FPs	RF	0.83 ± 0.05	0.28 ± 0.14	0.99 ± 0.01
Mol2vec	RF	0.83 ± 0.05	0.20 ± 0.15	1.00 ± 0.01


Jaeger et al., Mol2vec: Unsupervised Machine Learning Approach with Chemical Intuition. J Chem Inf Model 2018

ref
28
40
41
9
42
this work
this work

ref				
29				
43				
this work				
this work				

ref	
9	
5	
5	
this work	
this work	

Data Representation (convolutional neural networks)



- Process data that has a known grid-like structure (e.g., images, waveforms).
- Utilize a specialized linear operation • convolution.
- Advantages: sparse interactions, parameter sharing, and translational invariance.

Contribution

- provide an end-to-end learning framework:
 - > to learn fingerprint with better predictive performance
 - \succ the inputs are graphs with arbitrary size and shape

Efficient computation

>Fixed fingerprint must be large to encode all possible substructures >Neural fingerprint can be learned to encode relevant features for classification-> reduce the size

Neural fingerprint is more interpretable-> meaningful

Circular fingerprints	Neural graph fingerpri
1: Input:molecule, radius R , fingerprint length S 2: Initialize:fingerprint vector $\mathbf{f} \leftarrow 0_S$ 3: for each atom a in molecule do4: $\mathbf{r}_a \leftarrow g(a)$ \Rightarrow lookup atom features5: for $L = 1$ to R do \Rightarrow for each layer6:for each atom a in molecule do7: $\mathbf{r}_1 \dots \mathbf{r}_N = \text{neighbors}(a)$ 8: $\mathbf{v} \leftarrow [\mathbf{r}_a, \mathbf{r}_1, \dots, \mathbf{r}_N]$ \Rightarrow concatenate9: $\mathbf{r}_a \leftarrow \text{hash}(\mathbf{v})$ 10: $i \leftarrow \text{mod}(r_a, S)$ \Rightarrow Write 1 at index12:Return: binary vector \mathbf{f}	1: Input: molecule, radius R_{i} $H_{1}^{1} \dots H_{R}^{5}$, output weights W_{1} 2: Initialize: fingerprint vector f 3: for each atom <i>a</i> in molecule of 4: $\mathbf{r}_{a} \leftarrow g(a) > \text{lookup atom}$ 5: for $L = 1$ to R do $> \text{for each}$ 6: for each atom <i>a</i> in molecule 7: $\mathbf{r}_{1} \dots \mathbf{r}_{N} = \text{neighbors}(a)$ 8: $\mathbf{v} \leftarrow \mathbf{r}_{a} + \sum_{i=1}^{N} \mathbf{r}_{i}$ 9: $\mathbf{r}_{a} \leftarrow \sigma(\mathbf{v}H_{L}^{N}) > \text{smooth}$ 10: $\mathbf{i} \leftarrow \text{softmax}(\mathbf{r}_{a}W_{L})$ 11: $\mathbf{f} \leftarrow \mathbf{f} + \mathbf{i} > \text{add to f}$ 12: Return: real-valued vector


Every non-differentiable operation is replaced with a differentiable analog.


Duvenaud DK, Maclaurin D, Iparraguirre J, et al. Convolutional networks on graphs for learning molecular fingerprints, NIPS' 15

ints


- ?, weights $\dots W_R$ $\leftarrow \mathbf{0}_{S}$ do m features each layer ule **do** (a) ⊳ sum th function ▷ sparsify fingerprint r f


Neural graph fingerprints







Neural graph fingerprints







Neural graph fingerprints






Neural graph fingerprints





Neural graph fingerprints



This process is repeated many times to extract substructures with different levels

Experiment: predict solubility, drug efficacy, and organic photovoltaic efficiency

Dataset	Solubility	Drug efficacy	Photovolt	
Units	log Mol/L	EC ₅₀ in nM	percent	
Predict mean Circular FPs + linear layer Circular FPs + neural net Neural FPs + linear layer Neural FPs + neural net	$\begin{array}{c} 4.29 \pm 0.40 \\ 1.84 \pm 0.08 \\ 1.40 \pm 0.15 \\ 0.74 \pm 0.09 \\ \textbf{0.53} \pm \textbf{0.07} \end{array}$	$egin{array}{c} 1.47 \pm 0.07 \ 1.13 \pm 0.03 \ 1.24 \pm 0.03 \ 1.16 \pm 0.03 \ 1.17 \pm 0.03 \end{array}$		

Duvenaud DK, Maclaurin D, Iparraguirre J, et al. Convolutional networks on graphs for learning molecular fingerprints, NIPS' 15

ltaic efficiency

0.09 0.07 0.07 0.13 0.11

Summary of Molecular Representation

Traditional Molecular Representation

- 1D: properties
- 2D: Circular fingerprints e.g. ECFP

Neural network based molecular representation

- Mol2Vec
- Neural Fingerprint



Quantitative structure-activity relationship (QSAR) modeling



QSAR: Quantitative structure–activity relationship

Molecule Property Prediction

Intrinsic Properties Molar volume, molecular weight, connectivity indices **Chemical Properties** Molecule $f(\mathcal{V}) = \mathcal{V}$ property pKa, Log P, Solubility, Stability Drug molecule **Biological Properties**

Activity, Toxicity, Pharmacokinetics

Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships. Ma, Junshui, Robert P. Sheridan, Andy Liaw, George E. Dahl, and Vladimir Svetnik. 2015. Journal of Chemical Information and Modeling 55 (2): 263–74




Merck Molecular Activity Challenge

Help develop safe and effective medicines by predicting molecular activity. \$40,000 · 236 teams · 7 years ago

Overview Data Di	scussion Leaderboard Rules				
Overview					
Description	Help enable the development of safe, effective medicines.				
Prizes	When developing new medicines it is important to identify molecules that are highly active toward their				
Evaluationintended targets but not toward other targets that might cause side effects. The objective of this competition is to identify the best statistical techniques for predicting biological activities of differe					
Visualization-	molecules, both on- and off-target, given numerical descriptors generated from their chemical structures				
Prospect	The challenge is based on 15 molecular activity data sets, each for a biologically relevant target. Each row				
Submission-	corresponds to a molecule and contains descriptors derived from that molecule's chemical structure.				
Instructions	In addition to the prediction competition, Merck is also hosting a visualization challenge with a \$2,000				
Winners	prize for the most insightful and elegant graphical representations of the data.				
	Prizes total \$40,000 .				

Ma et al. 2015. "Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships." Journal of Chemical Information and Modeling 55 (2): 263–74.

Deep learning for Quantitative Structure-Activity Relationships (QSAR)




Ma et al. 2015. "Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships." *Journal of Chemical Information and Modeling* 55 (2): 263–74.


		data set	type		d	lescription	number of molecules	number of unique AP, descriptors
						Kaggle Data Sets		
Data	pooto and tooko	3A4 ADME		CYP P450 3A4 ii	nhibition —log(I		50000	9491
Udla	asets and tasks	CB1	target	binding to cannal	binoid receptor 1	1 –log(IC50) M	11640	5877
		DPP4	target	inhibition of dipe	ptidyl peptidase	4 –log(IC50) M	8327	5203
		HIVINT	target	inhibition of HIV	integrase in a ce	ell based assay –log(IC50) M	2421	4306
		HIVPROT	target	inhibition of HIV	′ protease −log(l	IC50) M	4311	6274
		LOGD	ADME	logD measured b	y HPLC method	1	50000	8921
		METAB	ADME	percent remainin	g after 30 min m	nicrosomal incubation	2092	4595
					kinin1 (substar	nce P) receptor binding –log(IC50) M	13482	5803
					1 1 receptor —le	$og(K_i)$ M	7135	4730
	15 tasks/datasets (k			- 1111	1 2 receptor —le	$og(K_i)$ M	14875	5790
	📕 🧹 tasks/datasets (k	<i>kaggle c</i>	omp	etition)	oprotein log(B	BA/AB)	8603	5135
	· ·	00	•	/	tein binding log	g(bound/unbound)	11622	5470
					ity) at 2 mg/kg	5	7821	5698
	+ 15 additional datas	sets			\4 inhibitions lo	og(IC50 without NADPH/IC50 with	5559	5945
			0		nhibition —log((IC50) M	6924	5552
						Additional Data Sets		
		2C8	ADME	CYP P450 2C8 ii	nhibition —log(I	C50) M	29958	8217
				_		50) M	189670	11730
	· · · · · · · · · · · · · · · · · · ·	107		<u> </u>	_	50) M	50000	9729
	Largest dataset has 3			mole	cules	-log(IC50) M	2763	5242
		, -				250) M	17469	6200
							50000	8959
	12 508	• • • •	· •			(clearance) μ L/min·mg	23292	6782
	and Z , JUO desc	criptors/f	eatu	res		50) M	12843	6596
		•				M	9536	6136
		FASSIF	ADME	solubility in simu	lated gut condition	ions log(solubility) mol/L	89531	9541
		HERG	ADME	inhibition of hER	G channel —log	(IC50) M	50000	9388
		HERG (full data set)	ADME	inhibition of hER	G ion channel –	-log(IC50) M	318795	12508
		NAV	ADME	inhibition of Nav	1.5 ion channel -	-log(IC50) M	50000	8302
		PAPP	ADME	apparent passive	permeability in F	PK1 cells log(permeability) cm/s	30938	7713
		PXR	ADME	induction of 3A4	by pregnane X r	receptor; percentage relative to rifampicin	50000	9282

Methods


- Previous state of the art
 - Random forest (RF)



 Fully connected neural networks with 1 or 2 hidden layers



Results on Kaggle competition data



Results on additional data

Table 3. Comparing RF with DNN Trained Using Recommended Parameter Settings on 15 Additional Datasets

data set	random forest (R ²)
2C8	0.158
2C9BIG	0.279
2D6	0.130
A-II	0.805
BACE	0.629
CAV	0.399
CLINT	0.393
ERK2	0.257
FACTORXIA	0.241
FASSIF	0.294
HERG	0.305
HERGfull	0.294
NAV	0.277
PAPP	0.621
PXR	0.333
mean	0.361

Avg improvement **13.9%** RF = .361 DNN = .411

individual DNN (R^2)

0.255
0.363
0.195
0.812
0.644
0.463
0.554
0.198
0.244
0.271
0.352
0.367
0.347
0.678
0.416
0.411

Automatic Generation of **Complementary Descriptors with Molecular Graph Networks**

J. Chem. Inf. Model. 2005, 45, 1159-1168

Automatic Generation of Complementary Descriptors with Molecular Graph Networks

Christian Merkwirth^{*,†,‡} and Thomas Lengauer^{*,†}

Computational Biology and Applied Algorithmics Group, Max-Planck-Institut für Informatik, Stuhlsatzenhausweg 85, 66123 Saarbrücken, Germany, and Department for Information Technology, Faculty of Physics, Astronomy, and Applied Computer Science, Jagiellonian University, Reymonta 4, 30-059 Kraków, Poland

Received December 20, 2004

1159

Motivation: How to automatically generate predictive chemical descriptors

 Chemical descriptors can quantify properties or characteristics of molecules, but expensive feature engineering is required




Figure source: <u>http://www.scbdd.com/chemdes/</u>

al descriptors eristics of




Molecular graph network (MGN)

- Molecule structure atoms as nodes, bonds as edges
- Feature net Graph neural network (1D node embedding)

$$x_i^{t+1} = \sum_{\text{atom } j \text{ adjacent to } i} A_{e_i,B_{ij}}^t y_j^t + c_{e_i}^t$$
$$y_i^{t+1} = \sigma(x_i^{t+1})$$

 Supervisor network – Fully connected feed forward neural net



Result

- Data: 42 000 compounds from the Developmental Therapeutics Program AIDS antiviral screen data set
 - 41,179 compounds: confirmed inactive (CI)
 - 1080 compounds: confirmed moderately active (CM) 0
 - 423 compounds: confirmed active (CA)
- Confusion matrix

-				
		predicted class		
	actual class	CI	СМ	
	CI	0.835	0.126	
	CM	0.408	0.380	
	CA	0.124	0.187	

CA 0.038 0.212 0.690

Convolutional Embedding of Attributed Molecular Graphs for Physical Property Prediction Connor W. Coley, Regina Barzilay, William H. Green, Tommi S. Jaakkola,

Connor W. Coley, Regina Barzilay, William H. Green, Tomm and Klavs F. Jensen

JOURNAL OF

CHEMICAL INFORMATION

July 2017


Convolutional Embedding of Molecular Graphs

Task: Given the molecular graph, predict Octanol solubility, Aqueous solubility, Melting point.

Intuition: "Predictive models can assist in lead optimization and in determining whether drug candidates should proceed to later development stages." To replace experimental High-Throughput Screening (HTS) to virtual HTS.

Coley et al. Convolutional Embedding of Attributed Molecular Graphs for Physical Property Prediction

Convolutional Embedding of Molecular Graphs



Undirected graphs with features on nodes and edges

Molecular Graphs as attribute graphs



#atoms



Convolutional Embedding of Molecular Graphs

Table 3. 5-Fold CV Performance on the Abraham Octanol Solubility Dataset, Averaged over Three Runs ⁴						
Model	Required data	Number of samples	MSE	MAE	SD	
Best SVM baseline	_	245°	0.467 ± 0.019	0.520 ± 0.008	0.680 ± 0.013	
GSE ³⁴	Melting point	223			0.71	
Abraham and Acree, no m.p. ³³	Four empirical descriptors	282 ^b			0.63	
Abraham and Acree, m.p. ³³	Four empirical descriptors and melting point	282 ^b			0.47	
CNN-Ab-oct-representative ^d	_	245 ^c	0.413 ± 0.018	0.496 ± 0.014	0.641 ± 0.011	
CNN-Ab-oct-representative	-	245 ^c	0.338 ± 0.005	0.455 ± 0.007	0.581 ± 0.005	
CNN-Ab-oct-consensus	_	245 ^c	0.328 ± 0.022	0.455 ± 0.015	0.573 ± 0.019	


Table 4. 5-Fold CV Performance on the Delaney Aqueous Solubility Dataset, Averaged over Three Runs^a

Model	Number of samples	MSE	MAE
Best SVM baseline	1116 ^b	1.255 ± 0.011	0.821 ± 0.006
Lusci et al. ¹⁸	1144	0.34	0.43
Duvenaud et al. ¹⁹	1144		0.52
CNN-De-aq-representative ^c	1116 ^b	0.334 ± 0.011	0.424 ± 0.005
CNN-De-aq-representative	1116 ^b	0.312 ± 0.003	0.401 ± 0.002
CNN-De-aq-consensus	1116 ^b	0.314 ± 0.008	0.403 ± 0.005

SD

 1.117 ± 0.004

 0.577 ± 0.010 0.559 ± 0.003 0.560 ± 0.007



Polyadic Regression and its Application to Chemogenomics Ioakeim Perros, Fei Wang, Ping Zhang, Peter Walker, Richard Vuduc, Jyotishman Pathak, and Jimeng Sun

In Proceedings of the 2017 SIAM International Conference on Data Mining (SDM 2017)












Chemogenomics methodology: Drug-induced, cell-specific gene expression analysis



Lab measurement y_{i_1,i_2,i_3} indicates effectiveness of drug i_1 towards treating tissue i_3 , w.r.t. gene i_2 .


Important for drug repositioning and revealing drug mechanisms

Challenges

- Not all drugs are measured across all tissues 1.
 - Expensive or impossible to measure




- 2. Exploit external knowledge and estimate expression for **new drugs**, for which we have **no measurements**
 - Focus on a small subset of targeted lab trials and cut down the costs



Problem: Polyadic Prediction

Predicted measurements are associated with ordered tuple of objects






$\mathcal{S} \times_1 \boldsymbol{x}_{i_1}^1 \times_2 \boldsymbol{x}_{i_2}^2 \cdots \times_K \boldsymbol{x}_{i_K}^K$: vector-tensor analogue of vector-matrix multiplication

Polyadic Regression core model

 $f(x_{i_1}^1, x_{i_2}^2, \cdots, x_{i_K}^K)$ $= b + \sum (\boldsymbol{w}^k)^\top \boldsymbol{x}_{i_k}^k + \sum (\boldsymbol{x}_{i_u}^u)^\top \mathbf{S}^{uv} \boldsymbol{x}_{i_v}^v$ k=1dyadic interactions linear terms $+\sum \mathcal{S}^{uvr} imes_1 oldsymbol{x}^u_{i_u} imes_2 oldsymbol{x}^v_{i_v} imes_3 oldsymbol{x}^r_{i_r} + \cdots$ uvrtriadic interactions $+ \mathcal{S} imes_1 oldsymbol{x}_{i_1}^1 imes_2 oldsymbol{x}_{i_2}^2 \cdots imes_K oldsymbol{x}_{i_K}^K$ general polyadic interactions

- Explores all inter-aspect interactions
- High model complexity







Real data description

- LINCS L1000 publicly-available drug-gene-tissue data: ~1000 genes, known to be maximally predictive
- 10 tissues with most expression profiles
- 850 genes for which we have similarity information (GOSemSim package in R)
- Drug features from PubChem: chemical structure of each drug


	Drugs	Genes	Tissues	Density	Value
Missing value	81	850	10	100%	688,5
New drug	500	850	10	44%	1,870,8

New drug experiment: constrain the train, validation and test sets to have no common drugs

LIBRARY OF INTEGRATED NETWORK-BASED CELLULAR SIGNATURES

les 500 .850

Task 1: Estimating missing measurements




- Linear terms: low predictive value
- MVMs: joint factorization and regularization (even if linear terms are irrelevant)
- FMs: competitive, but do not include 3order interactions
- Polyadic Regression: highest accuracy


Task 2: Predicting measurements for new drugs

Method	Spearman's ρ	#Pa
Polyadic Regression	0.23025 ± 0.0063886	
Factorization Machines	0.1252 ± 0.0083942	
Multi-view Machines	0.0669 ± 0.017242	
Ridge Regression	0.0061	

- Polyadic Regression achieves 0.1 increase in correlation between the predicted and the true vector of measurements
- **Robustness** for different initialization of parameters



Summary: Polyadic Regression




1) Estimate effectiveness of drug on tissues w.r.t. available genes 2) Predict for drugs unseen during training

Perros et al 2017. "Polyadic Regression and Its Application to Chemogenomics." SDM'17

Low Data Drug Discovery with **One-Shot Learning**

Altae-Tran, Han, Bharath Ramsundar, Aneesh S. Pappu, and Vijay Pande. 2017. ACS Central Science 3 (4): 283–93.


Motivation of one-shot learning for compound activity prediction



- How to find promising new drug candidates?
- How to find the candidates that are similar to the small number of active molecules?

Find promising new candidates

One shot learning for compound activity prediction



Great prediction results on two datasets with very limited training data

Table 1. ROC-AUC Scores of Models on Median Held-out Task for Each Model on Tox21 ^a					
	Tox21	RF (100 trees)	Graph Conv	Siamese	AttnLSTM
	10+/10-	0.586 ± 0.056	0.648 ± 0.029	0.820 ± 0.003	0.801 ± 0.001
	5+/10-	0.573 ± 0.060	0.637 ± 0.061	0.823 ± 0.004	0.753 ± 0.173
	1+/10-	0.551 ± 0.067	0.541 ± 0.093	0.726 ± 0.173	0.549 ± 0.088
	1+/5-	0.559 ± 0.063	0.595 ± 0.086	0.687 ± 0.210	0.593 ± 0.153
	1+/1-	0.535 ± 0.056	0.589 ± 0.068	0.657 ± 0.222	0.507 ± 0.079

Table 2. ROC-AUC Scores of Models on Median Held-out Task for Each Model on SIDER^a

SIDER	RF (100 trees)	Graph Conv	Siamese	AttnLSTM
10+/10-	0.535 ± 0.036	0.483 ± 0.026	0.687 ± 0.089	0.553 ± 0.058
5+/10-	0.533 ± 0.030	0.473 ± 0.029	0.648 ± 0.070	0.534 ± 0.053
1+/10-	0.540 ± 0.034	0.447 ± 0.016	0.544 ± 0.056	0.506 ± 0.016
1+/5-	0.529 ± 0.028	0.457 ± 0.029	0.530 ± 0.050	0.505 ± 0.022
1+/1-	0.506 ± 0.039	0.468 ± 0.045	0.510 ± 0.016	0.501 ± 0.022

10 active molecules, 10 inactive molecules

SIAMESE network, AttentionLSTM, and IterRefLSTM perform great

IterRefLSTM

 0.823 ± 0.002 0.830 ± 0.001 0.724 ± 0.008 0.795 ± 0.005 0.827 ± 0.001

IterRefLSTM

- 0.669 ± 0.007 0.704 ± 0.002 0.556 ± 0.011 0.644 ± 0.012
- $\textbf{0.697} \pm \textbf{0.002}$

But inconsistent/poor performance on some dataset

Table 3. ROC-AUC Scores of Models on Median Held-out Task for Each Model on MUV ^a					
MUV	RF (100 trees)	Graph Conv	Siamese	AttnLSTM	
10+/10-	0.754 ± 0.064	0.568 ± 0.085	0.601 ± 0.041	0.504 ± 0.058	
5+/10-	0.730 ± 0.063	0.565 ± 0.068	0.655 ± 0.166	0.507 ± 0.052	
1+/10-	0.556 ± 0.084	0.569 ± 0.061	0.602 ± 0.118	0.504 ± 0.044	
1+/5-	0.598 ± 0.067	0.554 ± 0.089	0.514 ± 0.053	0.515 ± 0.021	
1+/1-	0.559 ± 0.095	0.552 ± 0.084	0.500 ± 0.0001	0.500 ± 0.027	

- MUV dataset select structurally distinct positive examples.
- Poor performance on models leveraging structural similarity (SIAMESE, AttnLSTM, IterRefLSTM)

IterRefLSTM

 0.499 ± 0.053 0.663 ± 0.019 0.569 ± 0.012 0.632 ± 0.011 0.479 ± 0.037

And generalization across datasets is poor

Table 4. ROC-AUC Scores of Models Trained on Tox21 on Median SIDER Task for Each Model on SIDER⁴


SIDER from Tox21	Siamese	AttnLSTM	IterRefL
10+/10-	0.511 ± 0.031	0.509 ± 0.014	0.509 ±

 Even on the datasets which can be trained toward accurate models on themselves, those models do NOT generalize across datasets



LSTM 0.012

Summary: QSAR: Quantitative structure-activity relationship



Activity, Toxicity, Pharmacokinetics









